CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Pharmacologic Management of Patients With ADHD: Review of Guidelines

Last updated: March 18, 2016
Project Number: RC0759-000
Product Line: Rapid Response
Research Type: Drug
Report Type: Summary with Critical Appraisal
Result type: Report


  1. What are the evidence-based guidelines for the pharmacologic management of ADHD in children, adolescents, and adults?

Key Message

Stimulant drugs are the first-choice pharmacological treatment for ADHD in children, adolescents, and adults. Atomoxetine is the preferred initial choice of treatment when there is a risk that stimulant drugs may be abused/misused or diverted. Atomoxetine is also the recommended drug of choice when stimulant ADHD drugs are contra-indicated, ineffective, or poorly tolerated. There is limited evidence to support the efficacy or safety of combination therapy for ADHD comprising stimulant and non-stimulant drugs in patients with inadequate clinical response to monotherapy.